✓ Dispatched same or next working day · 2–3 day UK delivery
Commonly combined with ChemAesthetic GHRP6 10mg in research protocols.
Ratings are based on published research data and are for informational purposes only.
GHRP-6 is one of the original synthetic GH secretagogues, acting at ghrelin receptors to stimulate pulsatile GH release alongside appetite stimulation. Human studies demonstrate robust GH elevation within 30 minutes of administration. Unlike Ipamorelin, GHRP-6 significantly raises cortisol and prolactin, which some protocols consider a drawback.
Research Post
Growth Hormone Releasing Peptide-6 (GHRP-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) and one of the first characterised growth hormone secretagogues (GHS). Originally developed from enkephalin analogues in the 1980s, GHRP-6 played a foundational role in identifying the ghrelin receptor (GHSR-1a) and understanding GH pulse regulation.
GHRP-6 was synthesised by Cyril Bowers and colleagues at Tulane University as part of a programme investigating enkephalin opioid peptide analogues. Bowers observed unexpectedly potent GH-releasing activity from certain analogues that did not bind opioid receptors, indicating a novel receptor pathway. This work, spanning the late 1970s through the 1980s, eventually led to the discovery and characterisation of the ghrelin receptor (GHSR-1a) — a G-protein coupled receptor that mediates GH secretion from pituitary somatotrophs.
GHRP-6 became the reference compound for the GHS drug class and was central to understanding the endogenous ligand ghrelin, which was not discovered until 1999 (Kojima et al., Nature).
GHRP-6 binds GHSR-1a on pituitary somatotroph cells, stimulating GH release through multiple pathways: activation of phospholipase C, increased intracellular calcium, and inhibition of somatostatin release at hypothalamic level. Unlike GHRH, which acts exclusively through pituitary GHRH receptors, GHRP-6 also acts centrally in the hypothalamus and peripheral tissues where GHSR-1a is expressed.
GHRP-6 is less selective than newer GHRPs: at doses required for substantial GH release, it also stimulates cortisol and prolactin secretion to a measurable degree, and produces marked appetite stimulation via its ghrelin-like orexigenic effect in the arcuate nucleus.
In published human studies, GHRP-6 at 1 µg/kg IV produces peak GH at approximately 15–30 minutes with return to baseline by 60–90 minutes. Higher doses (10 µg/kg) produce correspondingly larger but not proportionally greater GH peaks, suggesting receptor saturation. Synergy with exogenous GHRH (and by extension CJC-1295 no DAC) follows the same dual-pathway mechanism seen with ipamorelin.
Bowers (1998) published comprehensive characterisation of GHRP-6 GH release kinetics in humans, including comparisons with GHRP-2 and ipamorelin. GHRP-6 produces larger GH peaks than ipamorelin at equivalent doses but with significantly more cortisol co-secretion — a property exploited in some research contexts where cortisol responses are the endpoint of interest.
GHRP-6's potent orexigenic effect, mediated via GHSR-1a activation in the hypothalamic arcuate nucleus, makes it a valuable tool in appetite regulation research. It mimics endogenous ghrelin signalling and has been used in preclinical models to study feeding behaviour, energy homeostasis, and the GH/appetite axis. Its use as a research tool is distinct from newer selective GHRPs precisely because its pleotropic activity makes it useful for studying the full GHSR-1a receptor pharmacology rather than isolated GH secretion.
A separate and growing body of research has investigated GHRP-6 in cardioprotection and hepatoprotection independent of its GH-releasing activity. Rodent models of ischaemia-reperfusion injury have demonstrated GHRP-6 pre-treatment reduces infarct size and myocardial apoptosis. This cardioprotective effect appears to involve activation of pro-survival PI3K/Akt and ERK1/2 signalling pathways at cardiac GHSR-1a sites and may be GH-independent (Gomes et al., 2016).
GHRP-2 and ipamorelin were developed subsequently with improved selectivity profiles. Ipamorelin in particular shows minimal cortisol and prolactin co-secretion. GHRP-6 remains valuable in research specifically because its broader pharmacological profile provides a more complete model of GHSR-1a physiology, including appetite, cortisol, and GH axis interactions simultaneously.
